← Eichor
Condition: Diffuse Glioma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Diffuse Glioma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Phase 1/Phase 2 · 3 location(s) · Institute of Cancer Research, United Kingdom · NCT06630260C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT04099797A Study of 177Lu-PSMA-617 in People With Gliomas
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07223034Combination Therapy for the Treatment of Diffuse Midline Gliomas
Phase 2 · 32 location(s) · University of California, San Francisco · NCT05009992FUS Etoposide for DMG
Phase 1 · 1 location(s) · Columbia University · NCT05762419Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Phase 1 · 2 location(s) · Emory University · NCT06624371Efficacy of a Mixed Distancial Neuropsychological Rehabilitation Program in Patients With Grade 2 or 3 Diffuse Glioma
NA · 8 location(s) · Institut du Cancer de Montpellier - Val d'Aurelle · NCT06468176Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT07468136Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Di
Phase 2 · 11 location(s) · Alpheus Medical, Inc. · NCT07225621Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Phase 1/Phase 2 · 1 location(s) · University of Miami · NCT05956821Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Di
Phase 1 · 20 location(s) · Children's Oncology Group · NCT06894979PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas
NA · 1 location(s) · Oslo University Hospital · NCT05190172Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
EARLY_Phase 1 · 1 location(s) · Mayo Clinic · NCT05717153Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors
NA · 1 location(s) · Tata Memorial Centre · NCT06831461ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Phase 1 · 7 location(s) · Sabine Mueller, MD, PhD · NCT04732065Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr
Phase 1 · 43 location(s) · National Cancer Institute (NCI) · NCT06860594PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Phase 2 · 13 location(s) · Nationwide Children's Hospital · NCT05096481Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
Phase 3 · 50 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT05476939Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial
Phase 2 · 2 location(s) · Mayo Clinic · NCT05077735rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Phase 1 · 3 location(s) · Ann & Robert H Lurie Children's Hospital of Chicago · NCT04943848ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Phase 2 · 20 location(s) · Nationwide Children's Hospital · NCT06838676A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) G
Phase 1/Phase 2 · 127 location(s) · National Cancer Institute (NCI) · NCT05099003Targeted Pediatric High-Grade Glioma Therapy
Phase N/A · 21 location(s) · Nationwide Children's Hospital · NCT05839379Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Phase 1/Phase 2 · 12 location(s) · Milton S. Hershey Medical Center · NCT0646519918F-Fluciclovine PET-MRI in High-grade Glioma
EARLY_Phase 1 · 1 location(s) · Children's Hospital of Philadelphia · NCT05553041Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma
Phase 1 · 1 location(s) · Capital Medical University · NCT05717699H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT07501156Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
Phase 1/Phase 2 · 1 location(s) · St. Jude Children's Research Hospital · NCT04923126
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.